Financial Analysis

NOTE 11 COMMITMENTS AND CONTINGENCIES As of April 30, 2026 and 2025, the Company has no commitments or contingencies. …

CommitmentsAndContingenciesDisclosureTextBlock · excerpt; the full note is in the filing

Schedule of disaggregated revenue For the Years ended April 30, Type of products or services Timing of revenue recognition 2026 2025 Other Services transferred over time $ 15,000 $ 10,838 Sales of dietary supplement Goods transferred at a point in time 1,947,620 2,651,267 Sales of food products Goods transferred at a point in time 1,062,918 TOTAL $ 3,025,538 $ 2,662,105 …

DisaggregationOfRevenueTableTextBlock · excerpt; the full note is in the filing

NOTE 7 - INCOME TAX EXPENSE The Company and its subsidiaries are subject to 21% federal corporate income tax rate in US and 6.5% New York state corporate income tax rate. The income tax provision for the years ended April 30, 2026 and 2025, consists of the following: Schedule of income tax provision Years ended April 30, 2026 2025 Federal Current $ 5,382 $ 310,699 Deferred (12,887 ) State Current 54,091 42,859 Deferred (3,151 ) Income tax provision $ 43,885 $ 353,558 As of April 30, 2026 and 2025, the Companys net deferred tax assets are as follows: Schedule of deferred tax assets As of April 30, 2026 2025 Deferred tax assets: Net operating loss $ $ 102,611 Bad debt expense 16,038 Total deferred tax assets 16,038 102,611 Less: valuation allowance (102,611 ) Deferred tax assets, net $ 16,038 $ The valuation allowance for deferred tax assets as of April 30, 2026 and 2025 was $ 0 and $ 102,611 , respectively. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The ultimate realization of deferred income tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred income tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. Based on consideration of these …

IncomeTaxDisclosureTextBlock · excerpt; the full note is in the filing

Recently Issued Accounting Pronouncements In October 2023, the FASB issued ASU No. 2023-06, Disclosure Improvements Codification Amendments in Response to the SECs Disclosure Update and Simplification Initiative. The ASU amends the disclosure or presentation requirements related to various subtopics in the FASB ASC. The ASU was issued in response to the SECs August 2018 final amendments in Release No. 33-10532, Disclosure Update and Simplification that updated and simplified disclosure requirements that the SEC believed were duplicative, overlapping, or outdated. The guidance in ASU 2023-06 is intended to align GAAP requirements with those of the SEC and to facilitate the application of GAAP for all entities. The amendments introduced by ASU 2023-06 are effective if the SEC removes the related disclosure or presentation requirement from its existing regulations by June 30, 2027. If, by June 30, 2027, the SEC has not removed the applicable requirements from its existing regulations, the pending content of the associated amendment will be removed from the ASC and will not become effective for any entities. Early adoption is permitted. The adoption of ASU 2023-06 is not expected to have a material impact on the Companys consolidated financial statements or related disclosures. In November 2024, the FASB issued ASU 2024-03, Income Statement Reporting Comprehensive Income Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (ASU 2024-03 …

NewAccountingPronouncementsPolicyPolicyTextBlock · excerpt; the full note is in the filing

NOTE 9 RELATED PARTY BALANCES AND TRANSACTIONS Nature of relationships with related parties Name of related party Relationship with the Company Rose Kelly (Ms. Kelly) Chief Executive Officer and Director of the Company Robert M. Kelly (Mr. Robert) Family member of Ms. Kelly Steve Niu (Mr. Niu) Chief Financial Officer of the Company On January 8, 2024, the Company granted 1,667 common stocks issuable per month in total of 20,000 common stocks to the Chief Financial Officer - Steve Niu, at fair value of $0.15 per share, subject to vesting conditions in completion of one year of service. For the years ended April 30, 2026 and 2025, the Company recognized share-based compensation in the amount of $ 0 and $ 2,000 , respectively. As of April 30, 2026 and 2025, the Companys common stock issuable under share-based compensation totaling $ 3,000 for 20,000 shares. During the year ended April 30, 2026 and 2025, Mr. Robert received compensation of $ 12,000 and $ 0 for his service. During the year ended April 30, 2026 and 2025, Ms. Kelly received compensation of $ 59,733 and $ 134,283 for her service. During the year ended April 30, 2026 and 2025, Mr. Niu received compensation of $ 24,000 and $ 8,000 for his service. …

RelatedPartyTransactionsDisclosureTextBlock · excerpt; the full note is in the filing

NOTE 3 SEGMENT REPORTING Currently, the Company has two reportable business segments: sale and distribution of dietary supplement and wholesale and trading of food products segment. In the following table, revenue is disaggregated by primary major product line, including a reconciliation of the disaggregated revenue with the reportable segments. Schedule of reconciliation of the disaggregated revenues Years ended April 30, 2026 Healthy Food Products Dietary Supplement Other Total Revenue from external customers: Consulting service income $ $ $ 15,000 $ 15,000 Sale of dietary supplement products 1,947,620 1,947,620 Sale of healthy food products 1,062,918 1,062,918 Total revenue 1,062,918 1,947,620 15,000 3,025,538 Cost of revenue: Consulting service income Sale of dietary supplement products (1,147,934 ) (1,147,934 ) Sale of healthy food products (967,015 ) (967,015 ) Total cost of revenue (967,015 ) (1,147,934 ) (2,114,949 ) Gross profit 95,903 799,686 15,000 910,589 Operating Expenses: Sales and distribution expenses (2,900 ) (2,900 ) Personal and benefit costs (43,591 ) (126,702 ) (170,293 ) General and administrative (231,778 ) (502,017 ) (733,795 ) Total operating expenses (275,369 ) (631,619 ) (906,988 ) Segment income (loss) $ (179,466 ) $ 168,067 $ 15,000 $ 3,601 For the Year ended April 30, 2025 Dietary Supplement Segment Consulting Service Segment Total Revenue from external customers: Consulting service income $ $ 10,838 $ 10,838 Sale of dietary supplement products …

SegmentReportingDisclosureTextBlock · excerpt; the full note is in the filing

NOTE 2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) and applicable rules and regulations of the U.S. Securities and Exchange Commission (the SEC). The financial statements are presented in US dollars, which is the Companys functional currency. Principles of Consolidation The consolidated financial statements include the financial statements of the Company and its subsidiary. All significant inter-company balances and transactions within the Company have been eliminated upon consolidation. Use of Estimates and Assumptions The preparation of the Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the dates of the consolidated financial statements, as well as the reported amounts of revenues and expenses during the reporting periods. These estimates and judgments include, but are not limited to, revenue recognition, allowance for credit losses, inventory impairment allowance, and deferred taxes. Management bases its estimates on historical experience and on various other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Although actual amou …

SignificantAccountingPoliciesTextBlock · excerpt; the full note is in the filing

NOTE 8 SHAREHOLDERS EQUITY Preferred Stock The Company is authorized to issue 10,000,000 shares of preferred stock, par value $ 0.001 per share, of which 3,000,000 shares of preferred stock have been designated as Series A Preferred Stock. Each share of Series A Preferred Stock shall entitle the holder to cast 20 votes, which votes shall be identical in all respects to, and counted on the same bases as, votes of shares of common stock and included in the totals for the common stock. Each share of Series A Preferred Stock is convertible at the option of the holder at any time into one share of common stock. The holders of Series A Preferred Stock shall not be entitled to receive dividends of any kind or be entitled to any liquidation preference. As of April 30, 2026 and 2025, no preferred stock has been issued and outstanding. Common Stock The Company is authorized to issue 200,000,000 shares of common stock, par value $ 0.001 per share, As of April 30, 2026 and 2025, 8,337,454 common stocks are issued and outstanding. On January 27, 2026, the Company's 1-for-3 reverse stock split of its common stock became effective, pursuant to which each holder of common stock received one share for every three shares held. The accompanying consolidated financial statements were retroactively reflected the reverse stock split for the periods presented. On January 8, 2024, the Company granted 1,667 common stocks issuable per month in total of 20,000 common stocks to the Chief Financial Offic …

StockholdersEquityNoteDisclosureTextBlock · excerpt; the full note is in the filing

NOTE 12 SUBSEQUENT EVENTS In accordance with ASC Topic 855, Subsequent Events, which establishes general standards of accounting for and disclosure of events that occur after the balance sheet date but before the consolidated financial statements are issued, the Company has evaluated all events or transactions that occurred after April 30, 2026, up to the date that the consolidated financial statements were available to be issued. …

SubsequentEventsTextBlock · excerpt; the full note is in the filing

NOTE 10 COMMITMENTS AND CONTINGENCIES As of July 31, 2026, the Company has no commitments or contingencies. …

CommitmentsAndContingenciesDisclosureTextBlock · excerpt; the full note is in the filing

Schedule of disaggregated revenue For the Three Months ended July 31, Type of products or services Timing of revenue recognition 2026 2025 Other Services transferred over time $ $ 4,225 Sales of dietary supplement Goods transferred at a point in time 87,000 99,674 Sales of food products Goods transferred at a point in time 234,576 TOTAL $ 321,576 $ 103,899 …

DisaggregationOfRevenueTableTextBlock · excerpt; the full note is in the filing

NOTE 6 - INCOME TAX The Company and its subsidiaries are subject to 21% federal corporate income tax rate in US and 6.5% New York state corporate income tax rate. There is no state income tax for Nevada state. The income tax provision for the three months ended July 31, 2026 and 2025, consists of the following: Schedule of income tax provision Three Months ended July 31, 2026 2025 Federal Current $ $ 10,585 Deferred State Current 939 3,276 Deferred Income tax provision $ 939 $ 13,861 As of July 31, 2026 and April 30, 2026, the Companys net deferred tax assets are as follows: Schedule of deferred tax assets As of July 31, 2026 As of April 30, 2026 Deferred tax assets: Net operating loss $ 25,310 $ Bad debt expense 16,038 16,038 Total deferred tax assets 41,348 16,038 Less: valuation allowance (25,310 ) Deferred tax assets, net $ 16,038 $ 16,038 The valuation allowance for deferred tax assets as of July 31, 2026 and April 30, 2026 was $ 25,310 and $ 0 , respectively. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The ultimate realization of deferred income tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred income tax liabilities, projected future taxable income, and tax planning strategies …

IncomeTaxDisclosureTextBlock · excerpt; the full note is in the filing

Recently Issued Accounting Pronouncements In October 2023, the FASB issued ASU No. 2023-06, Disclosure Improvements Codification Amendments in Response to the SECs Disclosure Update and Simplification Initiative. The ASU amends the disclosure or presentation requirements related to various subtopics in the FASB ASC. The ASU was issued in response to the SECs August 2018 final amendments in Release No. 33-10532, Disclosure Update and Simplification that updated and simplified disclosure requirements that the SEC believed were duplicative, overlapping, or outdated. The guidance in ASU 2023-06 is intended to align GAAP requirements with those of the SEC and to facilitate the application of GAAP for all entities. The amendments introduced by ASU 2023-06 are effective if the SEC removes the related disclosure or presentation requirement from its existing regulations by June 30, 2027. If, by June 30, 2027, the SEC has not removed the applicable requirements from its existing regulations, the pending content of the associated amendment will be removed from the ASC and will not become effective for any entities. Early adoption is permitted. The adoption of ASU 2023-06 is not expected to have a material impact on the Companys consolidated financial statements or related disclosures. In November 2024, the FASB issued ASU 2024-03, Income Statement Reporting Comprehensive Income Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (ASU 2024-03 …

NewAccountingPronouncementsPolicyPolicyTextBlock · excerpt; the full note is in the filing

NOTE 8 RELATED PARTY BALANCES AND TRANSACTIONS Nature of relationships with related parties Name of related party Relationship with the Company Rose Kelly (Ms. Kelly) Chief Executive Officer and Director of the Company Robert M. Kelly (Mr. Robert) Family member of Ms. Kelly Steve Niu (Mr. Niu) Chief Financial Officer of the Company Lawrence Yan (Mr. Yan) Chief Executive Officer of NTC On January 8, 2024, the Company granted 1,667 common stocks issuable per month in total of 20,000 common stocks to the Chief Financial Officer - Steve Niu, at fair value of $0.15 per share, subject to vesting conditions in completion of one year of service. For the three months ended July 31, 2026 and 2025, the Company recognized share-based compensation in the amount of $ nil and $ nil , respectively. As of July 31, 2026 and April 30, 2026, the Companys common stock issuable under share-based compensation totaling $ 3,000 for 20,000 shares. During the three months ended July 31, 2026 and 2025, Mr. Robert received compensation of $ 1,772 and nil for his service. During the three months ended July 31, 2026 and 2025, Ms. Kelly received compensation of $ 4,000 and nil for her service. During the three months ended July 31, 2026 and 2025, Mr. Niu received compensation of nil and $ 3,000 for his service. During the three months ended July 31, 2026 and 2025, Mr. Yan received compensation of $ 5,343 and nil for his service. …

RelatedPartyTransactionsDisclosureTextBlock · excerpt; the full note is in the filing

NOTE 3 SEGMENT REPORTING Currently, the Company has two reportable business segments: sale and distribution of dietary supplement and wholesale and trading of food products segment. In the following table, revenue is disaggregated by primary major product line, including a reconciliation of the disaggregated revenue with the reportable segments. Schedule of reconciliation of the disaggregated revenues Three Months ended July 31, 2026 Healthy Food Products Dietary Supplement Total Revenue from external customers: Sale of dietary supplement products $ $ 87,000 $ 87,000 Sale of healthy food products 234,576 234,576 Total revenue 234,576 87,000 321,576 Cost of revenue: Sale of dietary supplement products (63,180 ) (63,180 ) Sale of healthy food products (227,875 ) (227,875 ) Total cost of revenue (227,875 ) (63,180 ) (291,055 ) Gross profit 6,701 23,820 30,521 Operating Expenses Personal and benefit costs (20,883 ) (16,969 ) (37,852 ) General and administrative (78,884 ) (35,947 ) (114,831 ) Total operating expenses (99,767 ) (52,916 ) (152,683 ) Segment income (loss) $ (93,066 ) $ (29,096 ) $ (122,162 ) Three Months ended July 31, 2025 Dietary Supplement Other Total Revenue from external customers: Consulting service income $ $ 4,225 $ 4,225 Sale of dietary supplement products 99,674 99,674 Total revenue 99,674 4,225 103,899 Cost of revenue: Consulting service income Sale of dietary supplement products (35,118 ) (35,118 ) Total cost of revenue (35,118 ) (35,118 ) Gross profit 64 …

SegmentReportingDisclosureTextBlock · excerpt; the full note is in the filing

NOTE 2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared by management in accordance with both accounting principles generally accepted in the United States (GAAP), and the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Certain information and note disclosures normally included in audited consolidated financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to those rules and regulations, although the Company believes that the disclosures made are adequate to make the information not misleading. The unaudited condensed consolidated financial statements are presented in US dollars, which is the Companys functional currency. In the opinion of management, the condensed balance sheet as of April 30, 2026 which has been derived from audited consolidated financial statements and these unaudited condensed consolidated financial statements reflect all normal and considered necessary to state fairly the results for the periods presented. The results for the period ended July 31, 2026 are not necessarily indicative of the results to be expected for the entire fiscal year ending April 30, 2027 or for any future period. These unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the Managements Discussion and the audited consolidated financial stat …

SignificantAccountingPoliciesTextBlock · excerpt; the full note is in the filing

NOTE 7 SHAREHOLDERS EQUITY Preferred Stock The Company is authorized to issue 10,000,000 shares of preferred stock, par value $ 0.001 per share, of which 3,000,000 shares of preferred stock have been designated as Series A Preferred Stock. Each share of Series A Preferred Stock shall entitle the holder to cast 20 votes, which votes shall be identical in all respects to, and counted on the same bases as, votes of shares of common stock and included in the totals for the common stock. Each share of Series A Preferred Stock is convertible at the option of the holder at any time into one share of common stock. The holders of Series A Preferred Stock shall not be entitled to receive dividends of any kind or be entitled to any liquidation preference. As of July 31, 2026 and April 30, 2026, no preferred stock has been issued and outstanding. Common Stock The Company is authorized to issue 200,000,000 shares of common stock, par value $ 0.001 per share, As of July 31, 2026 and April 30, 2026, 8,337,454 common stocks are issued and outstanding. On January 27, 2026, the Companys 1-for-3 reverse stock split of its common stock became effective, pursuant to which each holder of common stock received one share for every three shares held. The accompanying consolidated financial statements were retroactively reflected the reverse stock split for the periods presented. On January 8, 2024, the Company granted 1,667 common stocks issuable per month in total of 20,000 common stocks to the Chie …

StockholdersEquityNoteDisclosureTextBlock · excerpt; the full note is in the filing

NOTE 11 SUBSEQUENT EVENTS In accordance with ASC Topic 855, Subsequent Events, which establishes general standards of accounting for and disclosure of events that occur after the balance sheet date but before the consolidated financial statements are issued, the Company has evaluated all events or transactions that occurred after July 31, 2026, up to the date that the consolidated financial statements were available to be issued. …

SubsequentEventsTextBlock · excerpt; the full note is in the filing